FTRE — Fortrea Holdings Inc.
NASDAQ · Healthcare · Biotechnology
$18.51
+$0.79 (+4.46%)
Fortrea Holdings Inc. (FTRE) is a biotechnology company listed on NASDAQ. It is led by Peter M. Neupert, based in 8 Moore Drive, Durham, NC, United States, 27709, with about 15,000 employees. Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures. In addition, it delivers phase I " IV clinical trial management, clinical pharmacology, and consulting services. Fortrea Holdings Inc. enters into a strategic collaboration with Emery Pharma to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction studies, to certify impurities are below the Acceptable Intake Limit set by U.S. Food and Drug Administration guidelines. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Latest reported FTRE revenue for 2025-09-30 was $701.3M. Net income was -$15.9M. Revenue was down 1.3% from 2025-06-30 to 2025-09-30. FTRE currently screens at market cap $433.7M.
Use this FTRE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the FTRE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the FTRE SEC filings page. Lician reads the product cache first so this HTML stays unique to Fortrea Holdings Inc. even when a live quote feed is slow.
About Fortrea Holdings Inc.
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures. In addition, it delivers phase I " IV clinical trial management, clinical pharmacology, and consulting services. Fortrea Holdings Inc. enters into a strategic collaboration with Emery Pharma to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction studies, to certify impurities are below the Acceptable Intake Limit set by U.S. Food and Drug Administration guidelines. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
FTRE Key Statistics
Market Cap
$433.69M
Volume
595,204
Previous Close
$18.27
Day Range
$17.99 – $18.55
EPS
-$3.67
Revenue
$2.70B
Net Income
-$328.50M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-5.1%
Profit Margin
-12.2%
Employees
15,000
FTRE Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $2.70B | $2.84B | $2.84B |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$328.50M | -$25.20M | $186.20M |
| EPS (Diluted) | -$3.67 | -$0.29 | $2.09 |
Total Assets
$3.58B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$118.50M
Operating Cash Flow
$262.80M
Free Cash Flow
$0.00
Fortrea Holdings Inc. Company Information
- Interim CEO, Chairman of the Board & Lead Independent Director
- Peter M. Neupert
- Headquarters
- 8 Moore Drive, Durham, NC, United States, 27709
- Website
- www.fortrea.com
- Phone
- 877 495 0816
- IPO / Founded
- 2023-07-03
- Sector
- Healthcare
- Industry
- Biotechnology